title: More randomization in phase II trials: necessary but not sufficient.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Rubinstein
authors.forename: Michael
authors.initials: M
authors.lastname: Leblanc
authors.forename: Malcolm A
authors.initials: MA
authors.lastname: Smith
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic / Q000379:methods / Q000592:standards; D017326:Clinical Trials, Phase III as Topic; D015986:Confounding Factors, Epidemiologic; D023381:Endpoint Determination; D019317:Evidence-Based Medicine; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods / Q000592:standards / Q000639:trends; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D012107:Research Design / Q000592:standards
chemical_list: D000970:Antineoplastic Agents